Shares of Silence Therapeutics plc (LON:SLN) hit a new 52-week high during trading on Tuesday . The company traded as high as GBX 244.75 ($3.25) and last traded at GBX 235 ($3.12), with a volume of 264,646 shares changing hands. The stock had previously closed at GBX 228 ($3.03).

The firm’s market capitalization is GBX 167.00 million. The company’s 50 day moving average price is GBX 189.17 and its 200 day moving average price is GBX 126.87.

In other news, insider Alistair Gray acquired 3,848 shares of the firm’s stock in a transaction that occurred on Wednesday, August 2nd. The stock was bought at an average cost of GBX 130 ($1.73) per share, for a total transaction of £5,002.40 ($6,646.82). Also, insider Andy Richards acquired 7,000 shares of the firm’s stock in a transaction that occurred on Monday, July 31st. The stock was purchased at an average price of GBX 147 ($1.95) per share, with a total value of £10,290 ($13,672.60).

TRADEMARK VIOLATION WARNING: “Silence Therapeutics plc (SLN) Reaches New 12-Month High at $244.75” was first posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece of content on another domain, it was copied illegally and reposted in violation of United States and international trademark & copyright laws. The correct version of this piece of content can be accessed at

About Silence Therapeutics plc

Silence Therapeutics plc is a United Kingdom-based ribonucleic acid (RNA) technology company. The Company is primarily involved in the research and development of pharmaceutical products. The Company’s technology harnesses the body’s natural mechanisms to create therapeutic effects within its own cells.

Receive News & Stock Ratings for Silence Therapeutics plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silence Therapeutics plc and related stocks with our FREE daily email newsletter.